Open AccessCorrection: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Author(s) -
Jesús Troya,
Pablo Ryan,
Esteban Ribera,
Daniel Podzamczer,
Víctor Hontañón,
José Alberto Terrón,
Vicente Boix,
Santiago Moreno,
Pilar Barrufet,
Manuel Castaño,
Ana Carrero,
Marı́a José Galindo,
Ignacio Suárez-Lozano,
Hernando Knobel,
Miguel Raffo,
Javier Solís,
María Yllescas,
Herminia Esteban,
Juan González-García,
Juan Berenguer,
Arkaitz Imaz
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0172184
Subject(s) - rilpivirine , abacavir , lamivudine , medicine , retrospective cohort study , human immunodeficiency virus (hiv) , antiretroviral drug , reverse transcriptase inhibitor , pharmacology , virology , antiretroviral therapy , viral load , hepatitis b virus , virus
[This corrects the article DOI: 10.1371/journal.pone.0164455.]